3 Stocks Under $1 Insiders Are Buying
3 Stocks Under $1 Insiders Are Buying
The Nasdaq Composite dropped by more than 500 points on Monday. Investors, meanwhile, focused on some notable insider trades.
納斯達克綜合指數週一下跌了 500 多點。與此同時，投資者專注於一些值得注意的內幕交易。
When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
當內部人士購買或出售股票時，表明他們對公司前景的信心或擔憂。對細價股感興趣的投資者和交易者可以認為這是他們整體投資或交易決策的一個因素。
Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.3
以下是最近一些細價股的著名內幕交易。有關更多信息，請查看 Beninga 的內幕交易平台。3
Rigel Pharmaceuticals
利格尔制药
- The Trade: Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) CEO, President Raul Rodriguez acquired a total of 1,000,000 shares at an average price of $0.69. To acquire these shares, it cost $688.4 thousand.
- What's Happening: Rigel Pharmaceuticals recently announced data from the FORWARD Phase 3 clinical trial of Fostamatinib did not demonstrate statistical significance in the primary efficacy endpoint.
- What Rigel Pharmaceuticals Does: Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's lead drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca.
- 貿易： 瑞格尔制药公司 （納斯達克：里格爾）首席執行官勞爾·羅德里格斯總統以 0.69 美元的平均價格獲得了 100 萬股。要收購這些股份，成本為 688.4 萬美元。
- 發生了什麼事： 瑞格爾製藥公司最近公佈了 Fostamatinib 前進 3 期臨床試驗的數據並未在主要療效終點中表現出統計意義。
- 瑞格爾藥品的作用是什麼： 瑞格爾製藥公司開發用於自身免疫性，癌症相關和病毒性疾病的小分子藥物。該公司的鉛藥是一種口服類風濕關節炎候選藥物，已獲得阿斯利康許可。
Recruiter.com Group
招聘網集團
- The Trade: Recruiter.com Group, Inc. (NASDAQ:RCRT) President and COO Miles Jennings acquired a total of 3,000 shares at an average price of $0.91. The insider spent around $2.73 thousand to buy those shares.
- What's Happening: Recruiter.Com Group, last month, posted a Q1 loss of $0.28 per share.
- What Recruiter.com Group Does: Recruiter.Com Group Inc is a hiring platform for the network of recruiters. The company empowers businesses to recruit specialized talent faster with virtual teams of recruiters and AI job-matching technology.
- 貿易: 招聘網集團股份有限公司 （納斯達克：RCRT）總裁和首席運營官邁爾斯詹寧斯以 0.91 美元的平均價格收購了共 3,000 股股票。內幕人士花了大約 2.73 萬美元購買這些股票。
- 發生了什麼: 上個月招聘網集團公佈第一季度虧損 0.28 美元。
- 招聘網集團做了什麼: 招聘網集團股份有限公司是一個招聘人才網絡的招聘平台。該公司使企業能夠通過招聘人員和 AI 工作匹配技術的虛擬團隊更快地招聘專業人才。
Also check this: Royal Caribbean Cruises And 2 Other Stocks Insiders Are Buying
另請檢查這個：皇家加勒比遊輪和 2 其他股票業內人士正在購買
Don't forget to check out our premarket coverage here .
別忘了在這裡查看我們的售前保障。
Creatd
Creatd
- The Trade: Creatd, Inc. (NASDAQ:CRTD) Executive Chairman Jeremy Frommer acquired a total of 1,031 shares at an average price of $0.90. To acquire these shares, it cost around $927.9.
- What's Happening: Creatd recently issued an update on its 2022 slate of three production projects.
- What Creatd Does: Creatd Inc empowers creators, brands, and entrepreneurs through technology and partnership. The company has three platforms, namely Creatd Labs, Creatd Ventures, and Creatd Partners.
- 貿易: 創造股份有限公司 (NASDAQ: CRTD) 執行主席弗羅梅爾以 0.90 美元的平均價格收購了共 1,031 股股份。要收購這些股票，其成本約為 927.9 美元。
- 發生了什麼: Creatd 最近發布了 2022 年三個生產項目的最新消息。
- 什麼新生物做: Creatd Inc 通過技術和合作夥伴關係賦予創作者，品牌和企業家的能力。該公司有三個平台，即 Creatd 實驗室，Creatd 企業和 Creatd 合作夥伴。
譯文內容由第三人軟體翻譯。